Title : Effects of somatostatin and oral potassium administration on terbutaline-induced hypokalemia.

Pub. Date : 1989 Jan

PMID : 2563217






5 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Terbutaline, a beta 2-adrenergic agonist, has been shown to cause hypokalemia and an increase of plasma glucose and serum insulin concentrations. Terbutaline insulin Homo sapiens
2 We considered that terbutaline-induced hypokalemia may be due to the insulin-induced shift of potassium (K+) from the extracellular to the intracellular space. Terbutaline insulin Homo sapiens
3 If so, then inhibition of insulin secretion by somatostatin would prevent terbutaline-induced hypokalemia. Terbutaline insulin Homo sapiens
4 Terbutaline caused a significant decrease of K+ (from 3.96 +/- 0.08 to 3.3 +/- 0.13 mmol/L +/- SEM; p less than 0.0005), accompanied by a significant increase in plasma glucose (from 83 +/- 3.6 to 101 +/- 4.4 mg/dl +/- SEM; p less than 0.01) and serum insulin concentrations (from 11.7 +/- 0.9 to 19.9 +/- 1.1 microU/ml +/- SEM; p less than 0.001), confirming earlier data. Terbutaline insulin Homo sapiens
5 In summary, the present findings confirm that terbutaline-induced hypokalemia is associated with increased plasma glucose and insulin levels. Terbutaline insulin Homo sapiens